IGFBP-rP10/KAZALD1 Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-90453
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Format
Concentration
Product Specifications
Immunogen
Reactivity Notes
Clonality
Host
Isotype
Description
Scientific Data Images for IGFBP-rP10/KAZALD1 Antibody - BSA Free
Immunohistochemistry-Paraffin: IGFBP-rP10/KAZALD1 Antibody [NBP1-90453]
Immunohistochemistry-Paraffin: IGFBP-rP10/KAZALD1 Antibody [NBP1-90453] - Staining of human spleen shows cytoplasmic positivity in spleen.Applications for IGFBP-rP10/KAZALD1 Antibody - BSA Free
Immunohistochemistry
Immunohistochemistry-Paraffin
Formulation, Preparation, and Storage
Purification
Formulation
Format
Preservative
Concentration
Shipping
Stability & Storage
Background: IGFBP-rP10
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. ALS (Acid Labile Subunit) is a liver-derived protein that exists in a ternary complex with Insulin-like Growth Factor (IGF)-binding Protein-3 (IGFBP-3) or IGFBP-5, and either IGF-I or IGF-II. ALS increases the half-life of IGF/IGFBP complexes in circulation.
Long Name
Alternate Names
Gene Symbol
Additional IGFBP-rP10 Products
Product Documents for IGFBP-rP10/KAZALD1 Antibody - BSA Free
Product Specific Notices for IGFBP-rP10/KAZALD1 Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.